LOGIN  |  REGISTER
Astria Therapeutics
Recursion

LifeMD to Participate in Two Investor Conferences in September

August 30, 2023 | Last Trade: US$5.57 0.17 -2.96

NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD) today announced that management will be participating in two upcoming investor conferences in September.

  • H.C. Wainwright 25th Annual Global Investment Conference, September 11-13, 2023 at the Lotte New York Palace Hotel in New York City. Management will deliver a company presentation on Wednesday, September 13th at 3:30 p.m. Eastern Time and will be available for one-on-one meetings with investors. A live and archived webcast of the presentation will be available in the Investors section of LifeMD’s website.
  • Cantor Fitzgerald Global Healthcare Conference, September 26-28, 2023 at the InterContinental New York Barclay in New York City. Management will participate in a fireside chat on Thursday, September 28th at 9:45 a.m. Eastern Time and will be available for one-on-one meetings during the event.

About LifeMD

LifeMD is a direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics and specialized treatment for men’s and women’s health, allergy & asthma and dermatologic conditions. By leveraging its proprietary technology platform, 50-state affiliated medical group and nationwide mail-order pharmacy network, LifeMD is making top-notch healthcare available and affordable to anyone. To learn more, go to LifeMD.com.

Company Contact:
LifeMD, Inc.
Marc Benathen, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page